← Back to Search

Vitamin D for COVID-19 (VIVID Trial)

Phase 3
Waitlist Available
Led By Davaasambuu Ganmaa, PhD
Research Sponsored by Brigham and Women's Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 8 weeks
Awards & highlights

VIVID Trial Summary

This trial is testing whether vitamin D supplements can reduce the rate of people seeking healthcare for symptoms related to COVID-19, and whether it can reduce the risk of infection with the virus in people who have been recently diagnosed with COVID-19.

Who is the study for?
The VIVID trial is for adults over 18 in the U.S. and Mongolia who've recently tested positive for COVID-19 or live with someone who has. Participants must not be in other COVID-19 trials, taking high doses of vitamin D, have severe kidney/liver disease, parathyroid conditions, take certain medications (for seizures/epilepsy), or have a history of hypercalcemia.Check my eligibility
What is being tested?
This study tests if daily vitamin D supplements can reduce healthcare visits related to COVID-19 symptoms and lower infection risk among household contacts compared to a placebo. It's randomized and placebo-controlled, meaning people are put into two groups by chance: one takes vitamin D and the other a dummy pill.See study design
What are the potential side effects?
Potential side effects from high doses of vitamin D may include elevated calcium levels leading to bone pain, digestive issues like nausea or constipation, fatigue, confusion, or heart rhythm problems. Placebo pills should not cause any direct side effects.

VIVID Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~8 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 8 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of seeking healthcare visits (including hospitalizations, emergency room visits, or ambulatory or virtual clinician visits) for symptoms or concerns related to COVID-19 or deaths in participants newly diagnosed with COVID-19 (index cases)
Secondary outcome measures
Disease severity in index cases
Disease symptom score in index cases
Long COVID symptoms in index cases
+3 more

VIVID Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Vitamin DActive Control1 Intervention
Daily vitamin D3 (9600 IU/day on days 1 and 2; 3200 IU/day on days 3 through 28)
Group II: PlaceboPlacebo Group1 Intervention
Placebo

Find a Location

Who is running the clinical trial?

Tishcon CorporationUNKNOWN
Harvard Medical School (HMS and HSDM)OTHER
195 Previous Clinical Trials
1,314,021 Total Patients Enrolled
Laboratory Corporation of AmericaIndustry Sponsor
27 Previous Clinical Trials
7,861 Total Patients Enrolled

Media Library

Placebo Clinical Trial Eligibility Overview. Trial Name: NCT04536298 — Phase 3
Coronavirus Research Study Groups: Vitamin D, Placebo
Coronavirus Clinical Trial 2023: Placebo Highlights & Side Effects. Trial Name: NCT04536298 — Phase 3
Placebo 2023 Treatment Timeline for Medical Study. Trial Name: NCT04536298 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
MetabolismJournal
Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action
Manson, JoAnn E., and Shari S. Bassuk. 2020. “Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action”. Metabolism. Elsevier BV. doi:10.1016/j.metabol.2020.154322.
MetabolismJournal
Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action
Manson, JoAnn E., and Shari S. Bassuk. 2020. “Commentary. Eliminating Vitamin D Deficiency During the COVID-19 Pandemic: A Call to Action”. Metabolism. Elsevier BV. doi:10.1016/j.metabol.2020.154322.
Contemporary Clinical TrialsJournal
The Vitamin D for COVID-19 (VIVID) Trial: A Pragmatic Cluster-randomized Design
Wang, Rui, Victor DeGruttola, Quanhong Lei, Kenneth H. Mayer, Susan Redline, Aditi Hazra, Samia Mora, Walter C. Willett, Davaasambuu Ganmaa, and JoAnn E. Manson. 2021. “The Vitamin D for COVID-19 (VIVID) Trial: A Pragmatic Cluster-randomized Design”. Contemporary Clinical Trials. Elsevier BV. doi:10.1016/j.cct.2020.106176.
clinicaltrials.govStudy
Vitamin D for COVID-19 Trial
JoAnn E. Manson, MD 2020. "Vitamin D for COVID-19 Trial". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04536298.
All > Prevention > Vitamin D
~96 spots leftby Jul 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top